Natural Product (NP) Details
| General Information of the NP (ID: NP1709) | |||||
|---|---|---|---|---|---|
| Name |
Salvianolic acid A
|
||||
| Synonyms |
Salvianolic acid A; 96574-01-5; (R)-3-(3,4-Dihydroxyphenyl)-2-(((E)-3-(2-((E)-3,4-dihydroxystyryl)-3,4-dihydroxyphenyl)acryloyl)oxy)propanoic acid; Salvianolic-acid-A; SALVIANOLIC ACID; CHEMBL457077; UNII-51622542XO; CHEBI:9017; Salvianolic acid A hydrate; 51622542XO; Dan Phenolic Acid A; Salvianolicacid; MFCD20527310; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid; AC1NQZ3H; Dan phenolic acid A hydrate; SCHEMBL19235589; BCP15440; HY-N0318; ZINC4098737; BDBM50414250; MFCD08458447; s9055; AKOS016009674; CCG-269648; DB15246; Salvianolic acid A, analytical standard; (2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3,4-dihydroxy-phenyl]prop-2-enoyl]oxy-propanoic acid; AS-75007; CS-0008816; N1803; X1224; C10492; 574S015; Q-100906; Q27108214; UNII-U5TCN455JO component YMGFTDKNIWPMGF-UCPJVGPRSA-N; (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-{2-[(1E)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl}prop-2-enoyl]oxy}propanoic acid; Benzenepropanoic acid, alpha-((3-(2-(2-(3,4-dihydroxyphenyl)ethenyl)-3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxy-, (R-(E,E))-
Click to Show/Hide
|
||||
| Species Origin | Salvia ... | Click to Show/Hide | |||
| Salvia | |||||
| Disease | Type 2 diabetes mellitus [ICD-11: 5A11] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-6.847
MDCK Permeability
-4.999
PAMPA
+++
HIA
- - -
Distribution
VDss
-0.687
PPB
98.1%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
-
CYP2B6 substrate
- - -
CYP2C8 inhibitor
++
HLM Stability
- - -
Excretion
CLplasma
12.496
T1/2
2.123
Toxicity
DILI
+++
Rat Oral Acute Toxicity
-
FDAMDD
+++
Respiratory
-
Human Hepatotoxicity
++
Ototoxicity
+++
Drug-induced Nephrotoxicity
+
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- - -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C26H22O10
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=C(C(=C(C=C2)O)O)C=CC3=CC(=C(C=C3)O)O)O)O
|
||||
| InChI |
1S/C26H22O10/c27-18-7-2-14(11-21(18)30)1-6-17-16(4-9-20(29)25(17)33)5-10-24(32)36-23(26(34)35)13-15-3-8-19(28)22(31)12-15/h1-12,23,27-31,33H,13H2,(H,34,35)/b6-1+,10-5+/t23-/m1/s1
|
||||
| InChIKey |
YMGFTDKNIWPMGF-UCPJVGPRSA-N
|
||||
| CAS Number |
CAS 96574-01-5
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Latamoxef | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Ten mice were challenged with 2 * 109 CFU S. aureus. | |||||
| Experimental
Result(s) |
The combination of salvianolic acid A with latamoxef completely protects mice against lethal pneumonia caused by methicillin-resistant Staphylococcus aureus. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | CDK5 activator 1 (CDK5R1) | Molecule Info | [3] | |
| DNA-binding factor KBF1 (p105) | Molecule Info | [4] | ||
| Forkhead box protein O3 (FOXO3) | Molecule Info | [5] | ||
| Glycogen synthase kinase-3 beta (GSK-3B) | Molecule Info | [3] | ||
| Heme oxygenase 1 (HMOX1) | Molecule Info | [6] | ||
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [6] | ||
| BioCyc | Heme degradation | Click to Show/Hide | ||
| KEGG Pathway | ErbB signaling pathway | Click to Show/Hide | ||
| 2 | Chemokine signaling pathway | |||
| 3 | Cell cycle | |||
| 4 | PI3K-Akt signaling pathway | |||
| 5 | Wnt signaling pathway | |||
| 6 | Hedgehog signaling pathway | |||
| 7 | Axon guidance | |||
| 8 | Hippo signaling pathway | |||
| 9 | Focal adhesion | |||
| 10 | Signaling pathways regulating pluripotency of stem cells | |||
| 11 | T cell receptor signaling pathway | |||
| 12 | B cell receptor signaling pathway | |||
| 13 | Neurotrophin signaling pathway | |||
| 14 | Dopaminergic synapse | |||
| 15 | Insulin signaling pathway | |||
| 16 | Melanogenesis | |||
| 17 | Prolactin signaling pathway | |||
| 18 | Thyroid hormone signaling pathway | |||
| 19 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 20 | Alzheimer's disease | |||
| 21 | Hepatitis C | |||
| 22 | Measles | |||
| 23 | Influenza A | |||
| 24 | HTLV-I infection | |||
| 25 | Epstein-Barr virus infection | |||
| 26 | Pathways in cancer | |||
| 27 | Colorectal cancer | |||
| 28 | Endometrial cancer | |||
| 29 | Prostate cancer | |||
| 30 | Basal cell carcinoma | |||
| 31 | Protein processing in endoplasmic reticulum | |||
| 32 | Porphyrin and chlorophyll metabolism | |||
| 33 | HIF-1 signaling pathway | |||
| 34 | Mineral absorption | |||
| 35 | MicroRNAs in cancer | |||
| 36 | MAPK signaling pathway | |||
| 37 | Ras signaling pathway | |||
| 38 | cAMP signaling pathway | |||
| 39 | NF-kappa B signaling pathway | |||
| 40 | Sphingolipid signaling pathway | |||
| 41 | Apoptosis | |||
| 42 | Osteoclast differentiation | |||
| 43 | Toll-like receptor signaling pathway | |||
| 44 | NOD-like receptor signaling pathway | |||
| 45 | RIG-I-like receptor signaling pathway | |||
| 46 | Cytosolic DNA-sensing pathway | |||
| 47 | TNF signaling pathway | |||
| 48 | Adipocytokine signaling pathway | |||
| 49 | Cocaine addiction | |||
| 50 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 51 | Shigellosis | |||
| 52 | Salmonella infection | |||
| 53 | Pertussis | |||
| 54 | Legionellosis | |||
| 55 | Leishmaniasis | |||
| 56 | Chagas disease (American trypanosomiasis) | |||
| 57 | Toxoplasmosis | |||
| 58 | Amoebiasis | |||
| 59 | Tuberculosis | |||
| 60 | Hepatitis B | |||
| 61 | Herpes simplex infection | |||
| 62 | Transcriptional misregulation in cancer | |||
| 63 | Viral carcinogenesis | |||
| 64 | Pancreatic cancer | |||
| 65 | Chronic myeloid leukemia | |||
| 66 | Acute myeloid leukemia | |||
| 67 | Small cell lung cancer | |||
| 68 | Inflammatory bowel disease (IBD) | |||
| NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
| 2 | IL1 Signaling Pathway | |||
| 3 | TCR Signaling Pathway | |||
| 4 | IL2 Signaling Pathway | |||
| 5 | TNFalpha Signaling Pathway | |||
| 6 | Leptin Signaling Pathway | |||
| Panther Pathway | Alzheimer disease-presenilin pathway | Click to Show/Hide | ||
| 2 | Angiogenesis | |||
| 3 | Cadherin signaling pathway | |||
| 4 | Hedgehog signaling pathway | |||
| 5 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 6 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 7 | Interleukin signaling pathway | |||
| 8 | PDGF signaling pathway | |||
| 9 | PI3 kinase pathway | |||
| 10 | Wnt signaling pathway | |||
| 11 | Ras Pathway | |||
| 12 | CCKR signaling map ST | |||
| 13 | Apoptosis signaling pathway | |||
| 14 | T cell activation | |||
| Pathwhiz Pathway | Porphyrin Metabolism | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
| 3 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
| 2 | Degradation of beta catenin | |||
| 3 | Reelin signaling pathway | |||
| 4 | Presenilin action in Notch and Wnt signaling | |||
| 5 | Integrin-linked kinase signaling | |||
| 6 | CDC42 signaling events | |||
| 7 | LKB1 signaling events | |||
| 8 | Canonical Wnt signaling pathway | |||
| 9 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 10 | Glucocorticoid receptor regulatory network | |||
| 11 | C-MYC pathway | |||
| 12 | Regulation of Androgen receptor activity | |||
| 13 | BMP receptor signaling | |||
| 14 | Hedgehog signaling events mediated by Gli proteins | |||
| 15 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 16 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 17 | Aurora A signaling | |||
| 18 | Insulin-mediated glucose transport | |||
| 19 | Class I PI3K signaling events mediated by Akt | |||
| 20 | p53 pathway | |||
| 21 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 22 | Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||
| 23 | HIF-1-alpha transcription factor network | |||
| 24 | Fc-epsilon receptor I signaling in mast cells | |||
| 25 | BCR signaling pathway | |||
| 26 | Atypical NF-kappaB pathway | |||
| 27 | Canonical NF-kappaB pathway | |||
| 28 | CD40/CD40L signaling | |||
| 29 | IL12-mediated signaling events | |||
| 30 | Alternative NF-kappaB pathway | |||
| 31 | Osteopontin-mediated events | |||
| 32 | Angiopoietin receptor Tie2-mediated signaling | |||
| 33 | Signaling events mediated by HDAC Class I | |||
| 34 | Regulation of Telomerase | |||
| 35 | IL1-mediated signaling events | |||
| 36 | TNF receptor signaling pathway | |||
| 37 | IL2 signaling events mediated by PI3K | |||
| 38 | Ceramide signaling pathway | |||
| 39 | amb2 Integrin signaling | |||
| 40 | IL23-mediated signaling events | |||
| 41 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
| 42 | EPO signaling pathway | |||
| Reactome | Degradation of beta-catenin by the destruction complex | Click to Show/Hide | ||
| 2 | AKT phosphorylates targets in the cytosol | |||
| 3 | Regulation of HSF1-mediated heat shock response | |||
| 4 | CRMPs in Sema3A signaling | |||
| 5 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
| 6 | S33 mutants of beta-catenin aren't phosphorylated | |||
| 7 | S37 mutants of beta-catenin aren't phosphorylated | |||
| 8 | S45 mutants of beta-catenin aren't phosphorylated | |||
| 9 | T41 mutants of beta-catenin aren't phosphorylated | |||
| 10 | Degradation of GLI2 by the proteasome | |||
| 11 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 12 | Iron uptake and transport | |||
| 13 | Activation of NF-kappaB in B cells | |||
| 14 | RIP-mediated NFkB activation via ZBP1 | |||
| 15 | Regulated proteolysis of p75NTR | |||
| 16 | NF-kB is activated and signals survival | |||
| 17 | Senescence-Associated Secretory Phenotype (SASP) | |||
| 18 | FCERI mediated NF-kB activation | |||
| 19 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
| 20 | Transcriptional regulation of white adipocyte differentiation | |||
| 21 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 22 | Interleukin-1 processing | |||
| 23 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
| 24 | IkBA variant leads to EDA-ID | |||
| 25 | CLEC7A (Dectin-1) signaling | |||
| 26 | CD209 (DC-SIGN) signaling | |||
| 27 | CLEC7A/inflammasome pathway | |||
| 28 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
| 29 | TRAF6 mediated NF-kB activation | |||
| WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
| 2 | Senescence and Autophagy in Cancer | |||
| 3 | Notch Signaling Pathway | |||
| 4 | Glycogen Metabolism | |||
| 5 | Insulin Signaling | |||
| 6 | Wnt Signaling Pathway | |||
| 7 | Wnt Signaling Pathway and Pluripotency | |||
| 8 | IL-6 signaling pathway | |||
| 9 | Wnt Signaling Pathway Netpath | |||
| 10 | Copper homeostasis | |||
| 11 | Focal Adhesion | |||
| 12 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 13 | Cardiac Hypertrophic Response | |||
| 14 | Degradation of beta-catenin by the destruction complex | |||
| 15 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 16 | Cardiac Progenitor Differentiation | |||
| 17 | BDNF signaling pathway | |||
| 18 | Corticotropin-releasing hormone | |||
| 19 | B Cell Receptor Signaling Pathway | |||
| 20 | IL17 signaling pathway | |||
| 21 | Neural Crest Differentiation | |||
| 22 | Alzheimers Disease | |||
| 23 | IL-7 Signaling Pathway | |||
| 24 | Regulation of Microtubule Cytoskeleton | |||
| 25 | TWEAK Signaling Pathway | |||
| 26 | Leptin signaling pathway | |||
| 27 | Semaphorin interactions | |||
| 28 | Cell Cycle | |||
| 29 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 30 | Androgen receptor signaling pathway | |||
| 31 | IL-5 Signaling Pathway | |||
| 32 | Oxidative Stress | |||
| 33 | Transcriptional activation by NRF2 | |||
| 34 | NRF2 pathway | |||
| 35 | Nuclear Receptors Meta-Pathway | |||
| 36 | Aryl Hydrocarbon Receptor Pathway | |||
| 37 | Mesodermal Commitment Pathway | |||
| 38 | Aryl Hydrocarbon Receptor | |||
| 39 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 40 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
| 41 | miR-targeted genes in squamous cell - TarBase | |||
| 42 | miR-targeted genes in muscle cell - TarBase | |||
| 43 | miR-targeted genes in lymphocytes - TarBase | |||
| 44 | miR-targeted genes in leukocytes - TarBase | |||
| 45 | miR-targeted genes in epithelium - TarBase | |||
| 46 | Toll-like receptor signaling pathway | |||
| 47 | SIDS Susceptibility Pathways | |||
| 48 | TCR Signaling Pathway | |||
| 49 | TGF Beta Signaling Pathway | |||
| 50 | IL-4 Signaling Pathway | |||
| 51 | Apoptosis Modulation by HSP70 | |||
| 52 | MAPK Signaling Pathway | |||
| 53 | Myometrial Relaxation and Contraction Pathways | |||
| 54 | IL1 and megakaryotyces in obesity | |||
| 55 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
| 56 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| 57 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
| 58 | Selenium Metabolism and Selenoproteins | |||
| 59 | Cytosolic sensors of pathogen-associated DNA | |||
| 60 | Fc epsilon receptor (FCERI) signaling | |||
| 61 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 62 | Signaling by the B Cell Receptor (BCR) | |||
| 63 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 64 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 65 | EBV LMP1 signaling | |||
| 66 | Apoptosis | |||
| 67 | Integrated Pancreatic Cancer Pathway | |||
| 68 | Oncostatin M Signaling Pathway | |||
| 69 | AGE/RAGE pathway | |||
| 70 | TNF alpha Signaling Pathway | |||
| 71 | TSLP Signaling Pathway | |||
| 72 | RANKL/RANK Signaling Pathway | |||
| 73 | Integrated Breast Cancer Pathway | |||
| 74 | Signalling by NGF | |||
| 75 | IL-1 signaling pathway | |||
| 76 | TCR signaling | |||
| 77 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 78 | Interleukin-1 signaling | |||
| 79 | Interleukin-1 processing | |||
| 80 | Apoptosis Modulation and Signaling | |||
| 81 | Folate Metabolism | |||
| 82 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
| 83 | Vitamin B12 Metabolism | |||
| 84 | Selenium Micronutrient Network | |||
| 85 | Regulation of toll-like receptor signaling pathway | |||
| 86 | Osteopontin Signaling | |||